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Abstract
Background: Radiation therapy is generally contraindicated for cancer patients with collagen
vascular diseases (CVD) such as scleroderma due to an increased risk of fibrosis. The tight skin
(TSK) mouse has skin which, in some respects, mimics that of patients with scleroderma. The skin
radiation response of TSK mice has not been previously reported. If TSK mice are shown to have
radiation sensitive skin, they may prove to be a useful model to examine the mechanisms underlying
skin radiation injury, protection, mitigation and treatment.
Methods: The hind limbs of TSK and parental control C57BL/6 mice received a radiation exposure
sufficient to cause approximately the same level of acute injury. Endpoints included skin damage
scored using a non-linear, semi-quantitative scale and tissue fibrosis assessed by measuring passive
leg extension. In addition, TGF-β1 cytokine levels were measured monthly in skin tissue.
Results: Contrary to our expectations, TSK mice were more resistant (i.e. 20%) to radiation than
parental control mice. Although acute skin reactions were similar in both mouse strains, radiation
injury in TSK mice continued to decrease with time such that several months after radiation there
was significantly less skin damage and leg contraction compared to C57BL/6 mice (p < 0.05).
Consistent with the expected association of transforming growth factor beta-1 (TGF-β1) with late
tissue injury, levels of the cytokine were significantly higher in the skin of the C57BL/6 mouse
compared to TSK mouse at all time points (p < 0.05).
Conclusion: TSK mice are not recommended as a model of scleroderma involving radiation injury.
The genetic and molecular basis for reduced radiation injury observed in TSK mice warrants
further investigation particularly to identify mechanisms capable of reducing tissue fibrosis after
radiation injury.
Background
Radiation fibrosis is frequently seen in patients undergo-
ing high dose curative radiotherapy. It has been described
in many tissues, including skin [1], lung [2]. Interestingly,
collagen vascular disease (CVD) patients, particularly
with scleroderma, are believed to be at increased risk of
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developing late complications of fibrosis after radiation
therapy [3-6]. The increased toxicity is a serious clinical
problem as many of these patients need radiation fre-
quently as a part of cancer treatment and during breast
conservation therapy for better cosmesis.
Cytokines, specifically Transforming growth beta 1 (TGF-
β1) is considered to play a central role in mediating radi-
ation induced tissue fibrosis [7]. Elevated levels of TGF-β1
have been associated with higher incidence of fibrosis
after thoracic and abdomino-pelvic radiotherapy [8]. An
abnormal increase in tissue TGF-β1 after radiation may
underlie excessive fibrosis seen in CVD patients. Under-
standing the dynamics of TGF-β1 regulation after radia-
tion in the setting CVD may be helpful in decreasing the
long term toxicities associated with radiation therapy.
Tight skin (TSK) mouse has been proposed for use as an
experimental animal model for scleroderma [9,10]. TSK
mice display features of dermal fibrosis similar to those
found in scleroderma [9]. The TSK phenotype results from
duplication of a central portion of the fibrillin-1 gene
[11]. Fibrillin-1 (FBN-1) is the major structural protein of
connective tissue microfibrils that are key components of
elastic fibers. The protein helps stabilize TGF-β in the
extracellular matrix [12] and acts as an extracellular reser-
voir of growth factors [13]. TSK mutation leads to the pro-
duction and secretion of a larger mutant FBN-1 protein
[14]. The mutant protein expresses an increase in the
number of TGF-β binding motifs resulting in more effi-
cient binding of TGF-β [15]. Also the altered FBN-1 con-
taining microfibrils become unstable and undergo
proteolysis readily in comparison to wild-type FBN-1
[16].
Mutations in FBN-1 are associated with various connec-
tive tissue disorders in humans including Marfan syn-
drome (MFS) [17]. Abnormal expression of FBN-1 has
also been noted in systemic sclerosis [18]. In the present
study, we correlated the TGF-β1 levels with tissue injury
and fibrosis seen after radiation in TSK mouse. The results
would establish TSK mouse as an animal model for stud-
ying radiation induced fibrosis in the setting of sclero-
derma.
Methods
15 mice aged five weeks were exposed to either two frac-
tions of 30 Gy (TSK mice) or two fractions of 25 Gy
(C57BL/6 mice) to the hind limbs. The damage to their
skin was scored using a semi-quantitative scale. Tissue
fibrosis was assessed by measuring passive leg extension.
Mice
Male TSK/+ mice, and parental C57BL/6 pa/pa mice (+/+)
were obtained from Jackson Laboratory (Bar Harbor, ME).
TSK mice are black and are heterozygous for a dominant
Fbn1Tsk mutation and a recessive Pldnpa mutation. There
is no indication that the recessive Pldnpa mutation con-
tributes to the phenotype of radiation damage.
All experiments performed in this study were approved by
and in accordance with the guidelines of the Institutional
Animal Care and Use Committee. The mice were kept in
individual separate cages under specific pathogen free
conditions before and throughout the experiments. This
prevents any skin damage that might have been caused by
the animals rather than radiation. The animals' health sta-
tus was checked daily by the scientific investigators, the
institutional animal care personnel and reviewed daily
with the staff veterinarian. On recommendation by the
staff veterinarian, animals were administered topical anti-
biotic and/or systemic analgesic (Buprenex).
Radiation treatment
Mice were anesthetized with an intraperitoneal injection
of ketamine (100 mg/kg) and xylazine (8 mg/kg). After
ten minutes, the animals, as many as ten at a time, were
positioned in a plexiglass jig that allowed radiation expo-
sure of the right posterior leg. Shielding was provided with
a square primary collimator (12 cm × 12 cm) and a circu-
lar secondary Cerrobend collimator (three 1/2 value lay-
ers). The dose rate from a 6 MV linear accelerator was 2.5
Gy/min, using 75 cm source to the surface distance. A 2.0
cm tissue equivalent bolus was used to bring the maximal
dose to the skin surface. Dose was prescribed to the Dmax
and mice received the fractionated schedule (24 hours
apart) as indicated for each experiment. Doses were con-
firmed using micro-TLD dosimetry.
Skin effects
Skin damage was assessed using a non-linear, semi-quan-
titative scale (Table 1) that is similar to previously
reported acute skin damage animal models [19]. Two
unblinded observers were also used to confirm the skin
damage score. Skin damage was measured approximately
weekly for 16 weeks.
Tissue fibrosis
Skin and tissue fibrosis attributable to radiation injury
was assessed adopting previously published solid tissue
endpoints of damage [20]. At multiple time points from
60 days onward passive leg extension from heel to the
medial aspect of the proximal leg (i.e. crotch) was meas-
ured with calipers. Skin damage and leg contraction was
measured in the same mouse.
TGF-β1 analysis
Quantitative estimation of TGF-β1 protein level in the
skin tissue was done at 0, 30, 60 and 90 days both in radi-
ated and control mice by enzyme-linked immunosorbentRadiation Oncology 2008, 3:40 http://www.ro-journal.com/content/3/1/40
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assay (ELISA) technique. Skin samples were weighed
before being mixed with tissue lysis buffer containing
0.5% Triton X-100, 2 ug/ml Aprotinin in 1× PBS to reach
a concentration of 40 mg of tissue/mL of buffer. After
homogenization and centrifugation, the supernatant was
withdrawn and stored at -80°C until analysis. Analysis
was carried out at different time points after radiation for
total TGF-β1, as well as for active TGF-β1, with commer-
cially available kits (Promega, Madison, WI). Measure-
ments of active and total amounts of TGF-β1 were
performed in separate steps. The active fraction of TGF-β1
was assayed directly in the ELISA plate using the kits pro-
vided. For measuring the total amount of TGF-β1, addi-
tional samples were acidified to pH 3.0 using 1 mol/L
HCl, followed by 15-min incubation at 22°C, resulting in
activation of all TGF-β1. To neutralise samples, 1 mol/L
NaOH was supplemented before application to the sec-
ond ELISA plate, according to the manufacturer's instruc-
tions. The results were normalized to total protein content
based on the method by Lowry using a commercial pro-
tein assay (Bio-Rad, Hercules, CA).
Statistics
Primary tests of significance between TSK and C57BL/6
mice were made for skin injury and leg extension. Skin
damage data were not normally distributed. In contrast,
leg extension data were normally distributed. Conse-
quently, the medians (and range) for skin damage and the
mean (with standard error of the means) for leg extension
measurements were employed. A nonparametric median
test was applied to the skin damage data to determine the
level of significance between TSK and C57BL/6 mice at
each of the two radiation doses. A two-way ANOVA test
was used for leg extension data to assess the significance
between the groups. For TGFβ1 analysis, Student's t test
was used to assess the difference between two groups.
Results
Radiation-induced Acute and Chronic Skin Reaction
Acute skin reactions were initially similar for the TSK and
C57BL/6 parental mouse strains. For example, skin inju-
ries up to six weeks following 60 Gy (2 fractions of 30 Gy
separated by 24 hours) and 50 Gy (2 fractions of 25 Gy
separated by 24 hours) were comparable in TSK and
C57BL/6 strains respectively (Fig 1a). This translates into
a radiation protection factor of 1.2 for TSK mouse. In
sharp contrast to the acute response, at between two
months and three months after radiation, a differential
response to radiation in the two strains was evident with
TSK mice showing less skin damage compared to C57BL/
6 mice (p < 0.05) (Fig 1a). C57BL/6 mice received lower
radiation dose compared to TSK mice as they tend to
develop severe damage after two fractions of 30 Gy.
Radiation-induced Leg Contraction
Measurements of radiation-induced leg contraction in
TSK and C57BL/6 mice starting at two months and contin-
uing to the end of the study paralleled the skin injury data.
TSK mice receiving 30 Gy × 2 had significantly less leg
contraction than C57BL/6 mice receiving 25 Gy × 2 (Fig
1b). The average leg extension at the end of the study
period was 8.3 mm in TSK mice compared to an average
Table 1: Semi-quantitative Skin damage scores
SCORE SKIN CHANGES
1.0 No effect
1.5 Minimal erythema, mild dry skin
2.0 Moderate erythema, dry skin
2.5 Marked erythema, dry desquamation
3.0 Dry desquamation, minimal dry crusting
3.5 Dry desquamation, dry crusting, superficial minimal scabbing
4.0 Patchy moist desquamation, moderate scabbing
4.5 Confluent moist desquamation, ulcers, large deep scabs
5.0 Open wound, full thickness skin loss
5.5 NecrosisRadiation Oncology 2008, 3:40 http://www.ro-journal.com/content/3/1/40
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Skin injury (panel A) and leg extension (panel B) in TSK (solid data points) and parental C57BL/6 mice (open data points) fol- lowing 60 Gy (TSK) or 50 Gy (C57BL/6) given as two equal radiation fractions separated by 24 hours Figure 1
Skin injury (panel A) and leg extension (panel B) in TSK (solid data points) and parental C57BL/6 mice (open 
data points) following 60 Gy (TSK) or 50 Gy (C57BL/6) given as two equal radiation fractions separated by 24 
hours. Each point for skin injury represents the median value for the group. The error bars represent minimum and maximum 
value of the range. Each point for leg extension data represents mean value for the group. The error bars represent the stand-
ard deviation of the mean.
Free (panel A) and total (panel B) transforming growth factor β1 (TGF-β1) measured in the skin tissue of TSK (solid data  points) and C57BL/6 (open data points) mice following 60 Gy (TSK) or 50 Gy (C57BL/6) given as two equal radiation fractions  separated by 24 hours Figure 2
Free (panel A) and total (panel B) transforming growth factor β1 (TGF-β1) measured in the skin tissue of TSK 
(solid data points) and C57BL/6 (open data points) mice following 60 Gy (TSK) or 50 Gy (C57BL/6) given as 
two equal radiation fractions separated by 24 hours. Each point for the TGF-β1 protein represents the mean value for 
the group. The error bars represent the standard deviation of the mean.Radiation Oncology 2008, 3:40 http://www.ro-journal.com/content/3/1/40
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leg extension of 1.0 mm in the C57BL/6 mice (p < 0.05)
(Fig 1b). The average leg extensions at the same time in
unirradiated TSK and C57BL/6 were 9.5 mm and 9 mm
respectively. The implication is that there was significantly
less fibrotic injury in TSK mice (Fig. 1b) compared to
C57BL/6 mice.
Analysis of TGF-β1 protein
The levels of both free and total TGF-β1 weren't statisti-
cally different in the five week old TSK and C57BL/6 mice
before radiation. But at days 30,60 and 90 after radiation
(Fig. 2), the quantity of both free and total TGF-β1 were
significantly higher in the skin of C57BL/6 mice com-
pared to TSK mice (p < 0.05). The TGF-β1 values corre-
lated with the degree of skin injury and fibrosis seen at the
end the study. The quantity of TGF-β1 in the skin of unir-
radiated C57/BL6 and TSK mice did not change signifi-
cantly during this period (data not shown).
Discussion
Our results evidently demonstrate that TSK mice are resist-
ant to radiation injury compared with the parental
C57BL/6 strain with respect to the manifestation of late
skin injury and fibrosis (Fig. 3). Even though both the TSK
mice and control mice showed similar degrees of skin
damage initially, the injury in TSK mice healed promptly
and ultimately exhibited signs of less fibrosis. This study
is the first report on the effects of radiation in an animal
model for scleroderma.
Collagen vascular disease is clinically considered a relative
contraindication for radiation therapy [21]. Scleroderma
patients are statistically at higher risk for radiation
induced complications in comparison to other collagen
vascular disorders [4,5]. There have been reports of exag-
gerated cutaneous and internal fibrotic reaction following
radiation therapy in scleroderma patients [3,22]. Conse-
quently, the expectation of radiation response in an exper-
imental model of scleroderma such as TSK mouse is for
increased skin damage and fibrosis. But compared to
parental C57BL/6 mice, TSK mice showed decreased radi-
ation induced skin injury and fibrosis.
The underlying causes of the fibrotic disorder characteris-
tic of unirradiated TSK mice have been a matter of debate.
One probable scenario is based on the observations that
increased TGF-β has an established association with
increased fibrosis and that the mutated FBN-1 binds more
TGF-β than the wild type [11]. In fact, deletion of TGF-β
in the heterozygote TSK mouse resulted in less fibrosis
[23]. It has been hypothesized that a breakdown of
mutant FBN-1 containing unstable microfibrils could lead
to a release of sequestered TGF-β which in turn could
stimulate fibrosis [16]. Increased TGF-β activity secondary
to abnormal FBN-1 leading to increased extracellular
matrix deposition has also been hypothesized in initiating
the fibrotic process [24].
The TGF-β family of proteins is synthesized as pro-pro-
teins in association with latency associated peptide (LAP)
which keeps the TGF-β in an inactive form [25]. The con-
Photograph of representative irradiated leg of TSK mice showing minor damage 110 days post-irradiation compared to paren- tal control Figure 3
Photograph of representative irradiated leg of TSK mice showing minor damage 110 days post-irradiation 
compared to parental control. The TSK mice had relatively normal legs (panel B) post-irradiation except for hair loss 
whereas parental control mice (panel A) showed extensive skin and leg injuries following the radiation exposure.Radiation Oncology 2008, 3:40 http://www.ro-journal.com/content/3/1/40
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centration of biologically active TGF-β is dependent on
the conversion from its latent form which requires disso-
ciation from LAP; a process termed latent TGF-β activa-
tion. The latent TGF-β binding protein (LTBP) binds
latent TGF-β and helps it's targeting to the extracellular
matrix [26]. The LTBP interacts with FBN-1 of the micro-
fibrils and stabilize latent TGF-β in the extra cellular
matrix [12]. Thus FBN-1 plays a critical role in the activa-
tion and signaling of TGF-β.
TGF-β has been implicated in the pathogenesis of diseases
such as MFS [27] and scleroderma [28,29]. Recently,
abnormal FBN-1 has been hypothesized to be the cause
aberrant TGF-β signaling in scleroderma [24]. It seems
that an altered FBN-1/TGF-β pathway is common to
pathogenesis MFS, scleroderma and TSK mouse.
We measured the levels of TGF-β1 in irradiated TSK and
C57BL/6 mice skin and correlated them with the level of
tissue injury and fibrosis. Both free (active) and total TGF-
β1 was higher in C57BL/6 mouse skin at all time points
after radiation compared to the TSK mouse and correlated
well with the higher degree of skin injury and fibrosis seen
in C57BL/6 mouse after radiation. This seems counter
intuitive as TSK mice were expected to show greater fibro-
sis after radiation due to their aberrant TGF-β1 signaling.
Similar to TSK mouse, even though dysregulation of TGF-
β1 activation secondary to mutation in FBN-1 is impli-
cated in pathogenesis of MFS, patients with MFS appar-
ently tolerate radiation treatment [30]. In contrast,
scleroderma patients are known to be at risk of increased
fibrosis after radiation therapy.
There may be several possible reasons for the observed
results. Tight binding of TGF-β1/LTBP to the abnormal
FBN-1 may result in decreased release of the biologically
active TGF-β1 in TSK mice after tissue injury. Indeed, radi-
ation is known to induce activation of latent TGF-β1 to its
active form in vivo [31]. This seems not to be the case as we
observed lower levels of both free and bound TGF-β1
(after acid activation) in the TSK mouse skin compared to
C57BL/6 mouse. Alternatively, breakdown of unstable
microfibrils could lead depletion of TGF-β1 stores and
may blunt TGF-β1 mediated effects including fibrosis after
radiation injury. The heterozygote TSK/+ mouse also pro-
duces comparable amounts of normal FBN-1 molecule
along with larger abnormal FBN-1 molecule [14]. But this
doesn't seem to increase the local TGF-β1 availability after
radiation injury in TSK mice. It may also be that the
abnormal FBN-1 molecule protects TSK mice from radia-
tion induced skin injury by a mechanism not involving
TGF-β1.
Conclusion
Based on the data presented, we conclude that the TSK
mouse is not a suitable model to study the effects of radi-
ation in case of scleroderma. Further studies are required
to elucidate the role of FBN-1 in controlling TGF-β1 sign-
aling in TSK mouse. The underlying mechanism of radia-
tion resistance in TSK mouse can be exploited to prevent
long term fibrosis in patients undergoing radiation ther-
apy.
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